Sign in Subscribe
Chemotherapy

Xenografts in Ovarian Cancer Research: Understanding the Potential of Patient-Derived Xenograft Organs (PDXOs)

Strategic Insights

— 1 min read

Research has been ongoing at the University of New Mexico Health Sciences Center to identify effective therapies for ovarian cancer, which remains the deadliest gynecological cancer due to late-stage diagnosis and high rates of chemotherapy resistance and recurrence. To address this challenge, researchers have been exploring the use of patient-derived xenograft (PDX) models, which can provide a renewable source of cancer cells for testing candidate therapies in vivo. A recent study published in BMC Cancer demonstrates that PDX-derived organoids (PDXOs) can reflect patient responses to chemotherapy similarly to primary patient-derived organoids (PDOs).

Key Takeaways:

  • The study involved establishing 3D organoid models from the malignant ascites of five high-grade serous ovarian cancer patients, with two platinum-sensitive, two platinum-resistant, and one platinum-refractory responses.
  • The in vitro drug responses of PDXOs and PDOs were compared to defined patient clinical responses, showing that PDXOs respond to drugs similarly to PDOs.
  • The study highlights the potential of PDXOs as renewable models for screening novel therapies and developing personalized strategies in OC.
  • The research implies that organoid models, including PDXOs, can effectively mimic the tumor's 3D structure and preserve intra-tumoral heterogeneity, making them suitable for personalized drug response studies.
  • The use of PDX models can provide a renewable source of cancer cells for organoids, addressing the limitation of primary tissue supply.
  • The study's conclusion emphasizes the importance of PDXOs in understanding the platinum sensitivity of ovarian cancer patients and developing effective therapies.

Statistics:

  • 5 high-grade serous ovarian cancer patients were involved in the study, with 2 platinum-sensitive, 2 platinum-resistant, and 1 platinum-refractory responses.
  • 3D organoid models were established from malignant ascites and compared to PDX samples from ascites and solid tumor.
  • The study used paclitaxel (PTX), carboplatin (CBDCA), or their combination in vitro treatment of PDXOs and PDOs, with a 72-hour treatment duration.
  • The study found that PDXOs responded to drugs similarly to PDOs, with a 6-month post-treatment response to standard platinum/paclitaxel therapy.

Sources:

  • Organoid models established from primary tumors and patient-derived xenograft tumors reflect platinum sensitivity of ovarian cancer patients. BMC Cancer, 2025,25(1):1-12.
  • Parisa Nikeghbal, Department of Pathology, University of New Mexico Health Sciences Center
  • Dorsa Zamanian, Danielle Burke, Mara P. Steinkamp (additional authors)
  • University of New Mexico Health Sciences Center
  • BMC Cancer (publisher)
  • https://doi-org.sdpl.idm.oclc.org/10.1186/s12885-025-14811-8 (free version of the journal article)

Read more